Flora Natura® Visage Boost Ultra Firm
Food supplement declared in France, decision dated 2 September 2026
Flora Natura® Visage Boost Ultra Firm, from Scientia Natura Distribution, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Filipendula ulmaria 500 mg per day, Taraxacum campylodes 500 mg per day, Calluna vulgaris 500 mg per day, Tilia cordata 500 mg per day, Aloe vera 200 mg per day. 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- Flora Natura
- Food business operator placing the product on the market
- Scientia Natura Distribution
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Ampoule
- Daily dose
- 2
- Directions for use
- Prendre 1 à 2 ampoules par jour pendant un repas
- Intended populations
- General population
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Allergy to salicylate derivatives, Pregnant women, Taking anticoagulants, Taking medication, Ulcer (stomach or duodenum)
- Objectives stated by the manufacturer (these are not authorised claims)
- Skin
Declaration 373986, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Filipendula ulmaria (L.) Maxim. | Parties aériennes | Extrait fluide aqueux | 500 mg |
| Taraxacum campylodes G.E.Haglund | Racine | Extrait fluide aqueux | 500 mg |
| Calluna vulgaris (L.) Hull | Sommités fleuries | Extrait fluide aqueux | 500 mg |
| Tilia cordata Mill. | Aubier | Extrait fluide aqueux | 500 mg |
| Aloe vera (L.) Burm. f. | Feuille (gel) | Extrait fluide aqueux | 200 mg |
| Primula veris L. | Fleur | Extrait fluide aqueux | 20 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Membrane d'oeuf | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
Additives
E950
Other ingredients
jus de raisin, jus de pomme, eau
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Déconseillé en cas d'occlusion intestinale, de maladie inflammatoire intestinale aigüe ou chronique, de douleurs abdominales d'origine inexpliqué, de déshydratation sévère ou d'hypokaliémie. Déconseillé en cas de gastrite ou d'ulcère gastro-duodénal. Déconseillé en cas d'allergie croisée connue (en particulier aux plantes du genre Primula). Déconseillé aux personnes souffrant d'allergie ou d'hypersensibilité aux dérivés salicylés (aspirine). L'emploi chez les personnes sous traitement anti-coagulant et chez les enfants et les adolescents est déconseillé. Réservé aux adultes. Déconseillé aux femmes enceintes ou allaitantes. En cas de traitements médicamenteux, demander conseil à un professionnel de santé. Déconseillé en cas d'obstructions biliaires, d'insuffisance cardiaque ou rénale œdémateuses. Déconseillé en cas d'allergie croisée connue, en particulier aux plantes de la famille des Asteraceae.
Regulatory points
- Conditions légales
Aloe vera (L.) Burm. f.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Filipendula ulmaria (L.) Maxim.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux personnes souffrant d'allergie aux dérivés salicylés.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Taraxacum campylodes G.E.Haglund
Read the warning, when it applies and the studies cited
DANDELION - TARAXACUM OFFICINALE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder or an intestinal obstruction (Brinker 2010; Godfrey et al. 2010; ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (5)
- Bradley PR, editor. 1992. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Godfrey A, Saunders P, Barlow K, Gowan M. Principles and Practices of Naturopathic Botanical Medicine: Volume 1: Botanical Medicine Monographs, 1st edition. Toronto (ON): CCNM Press Inc.; 2010.
- EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Consulté le 14 mars 2024]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
Condition of application: Constipation, Flushing of the urinary tract, Indigestion, and Loss of appetite.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Applies to products providing 10 g or more of dried leaf or dried root or dried whole plant, per day or 10 mL or more of juice, per day.
Do not use if you have diabetes or a blood pressure, kidney or cardiovascular disorder (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).
Sources cited by Health Canada (8)
- Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966;51(6):1046-1053. PubMed
- Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. British Medical Journal 1990;300(6730):975-978. PubMed Randomised trial
- EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
- Goksu E, Eken C, Karadeniz O, Kucukyilmaz O, Firt report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion. The American Journal of Emergency Medicine 2010;28:111.e1-111.e2
- Green DM, Ropper AH, Kronmal RA, Psaty BM, Burke GL. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002;59(3):314-320. PubMed
- Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr. SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
- Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73(1):114-123. PubMed
- Mujais SK, Katz AL. Potassium deficiency. In: Seldin & Giebisch's The Kidney: Physiology and Pathophysiology. Lippincott Williams and Wilkins; 2000. p1615.
Do not use if you are taking heart medications or other products containing diuretics (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).
Sources cited by Health Canada (8)
- Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966;51(6):1046-1053. PubMed
- Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. British Medical Journal 1990;300(6730):975-978. PubMed Randomised trial
- EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
- Goksu E, Eken C, Karadeniz O, Kucukyilmaz O, Firt report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion. The American Journal of Emergency Medicine 2010;28:111.e1-111.e2
- Green DM, Ropper AH, Kronmal RA, Psaty BM, Burke GL. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002;59(3):314-320. PubMed
- Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr. SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
- Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73(1):114-123. PubMed
- Mujais SK, Katz AL. Potassium deficiency. In: Seldin & Giebisch's The Kidney: Physiology and Pathophysiology. Lippincott Williams and Wilkins; 2000. p1615.
- Tilia cordata Mill.
Read the warning, when it applies and the studies cited
Linden - TILIA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; De Smet 1993).
Sources cited by Health Canada (2)
- De Smet PAGM, Keller K, Hansel R, Chandler RF, editors. Adverse Effects of Herbal Drugs, Volume 2. Berlin (DE): Springer-Verlag; 1993.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Aloe vera (L.) Burm. f.
Read the warning, when it applies and the studies cited
ALOE VERA LEAF GEL - Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005; Bartram 1998).
Sources cited by Health Canada (3)
- Bartram T. Bartram's Encyclopedia of Herbal Medicine, 1st edition. London (GB): Robinson Publishing Ltd; 1998.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Applies to products providing 2.4 g or more fresh leaf gel, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Huseini et al. 2012; Pizzorno and Murray 2006).
Sources cited by Health Canada (2)
- Huseini HF, Kianbakht S, Hajiaghaee R, Dabaghian FH. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Planta Medica 2012;78(4):311-316. PubMed Randomised trial
- Pizzorno J E, Murray M T. Text Book of Natural Medicine, 3rd edition. St. Louis (MO): Elsevier Churchill Livingstone; 2006.
Condition of application: Demulcent.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 28 March 2025
ALOE - ALOE VERA/ALOE FEROX - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
- Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
- Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.
Contraindications
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.
Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
- Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.
Known adverse reactions
Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2016; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
Health Canada monograph dated 28 March 2025
ALOE - ALOE VERA Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M. éditeurs. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press; 2013.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Flora Natura
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Flora Natura® Visage Boost Ultra Firm: composition and regulation”, https://compoatlas.com/en/supplements/products/373986-flora-natura-visage-boost-ultra-firm, updated 15 November 2026.